Skip to main content

Demetria J. Smith-Graziani, MD, MPH

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology